It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Antigenically distinct SARS-CoV-2 variants increase the reinfection risk for vaccinated and previously exposed population due to antibody neutralization escape. COVID-19 severity depends on many variables, including host immune responses, which differ depending on genetic predisposition. To address this, we perform immune profiling of female mice with different genetic backgrounds –transgenic K18-hACE2 and wild-type 129S1– infected with the severe B.1.351, 30 days after exposure to the milder BA.1 or severe H1N1. Prior BA.1 infection protects against B.1.351-induced morbidity in K18-hACE2 but aggravates disease in 129S1. H1N1 protects against B.1.351-induced morbidity only in 129S1. Enhanced severity in B.1.351 re-infected 129S1 is characterized by an increase of IL-10, IL-1β, IL-18 and IFN-γ, while in K18-hACE2 the cytokine profile resembles naïve mice undergoing their first viral infection. Enhanced pathology during 129S1 reinfection cannot be attributed to weaker adaptive immune responses to BA.1. Infection with BA.1 causes long-term differential remodeling and transcriptional changes in the bronchioalveolar CD11c+ compartment. K18-hACE2 CD11c+ cells show a strong antiviral defense expression profile whereas 129S1 CD11c+ cells present a more pro-inflammatory response upon restimulation. In conclusion, BA.1 induces cross-reactive adaptive immune responses in K18-hACE2 and 129S1, but reinfection outcome correlates with differential CD11c+ cells responses in the alveolar space.
Genetic disposition can impact response to virus infection. Here, the authors used a reinfection approach with antigenically distinct SARS-CoV-2 variants Omicron and Beta and show that differences in the immune response correlate with disease outcome in mouse models with different genetic background upon reinfection.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Icahn School of Medicine at Mount Sinai New York, Department of Microbiology, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351); Icahn School of Medicine at Mount Sinai New York, Global Health and Emerging Pathogens Institute, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351)
2 Icahn School of Medicine at Mount Sinai New York, Department of Microbiology, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351); Icahn School of Medicine at Mount Sinai New York, Global Health and Emerging Pathogens Institute, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351); Icahn School of Medicine at Mount Sinai, Graduate School of Biomedical Sciences, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351)
3 Icahn School of Medicine at Mount Sinai New York, Department of Microbiology, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351); Icahn School of Medicine at Mount Sinai New York, Global Health and Emerging Pathogens Institute, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351); Ghent University, Department of Pharmaceutics, Ghent, Belgium (GRID:grid.5342.0) (ISNI:0000 0001 2069 7798)
4 Civil Hospital, RT-PCR COVID−19 Laboratory, Moga, India (GRID:grid.59734.3c)
5 Sanford-Burnham Prebys Medical Discovery Institute, NCI Designated Cancer Center, La Jolla, USA (GRID:grid.479509.6) (ISNI:0000 0001 0163 8573)
6 Icahn School of Medicine at Mount Sinai New York, Department of Microbiology, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351); Icahn School of Medicine at Mount Sinai New York, Global Health and Emerging Pathogens Institute, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351); Icahn School of Medicine at Mount Sinai, Lipschultz Precision Immunology Institute (PrIISM), New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351); Icahn School of Medicine at Mount Sinai, Icahn Genomics Institute, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351)
7 University of Wyoming, Department of Veterinary Sciences, Laramie, USA (GRID:grid.135963.b) (ISNI:0000 0001 2109 0381)
8 Icahn School of Medicine at Mount Sinai New York, Department of Microbiology, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351); Icahn School of Medicine at Mount Sinai New York, Global Health and Emerging Pathogens Institute, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351); Icahn School of Medicine at Mount Sinai New York, Department of Medicine, Division of Infectious Diseases, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351); Icahn School of Medicine at Mount Sinai New York, The Tisch Cancer Institute, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351)